{"id":58592,"date":"2024-06-25T12:00:17","date_gmt":"2024-06-25T12:00:17","guid":{"rendered":"https:\/\/biomedpharmajournal.org\/?p=58592"},"modified":"2024-07-03T16:39:25","modified_gmt":"2024-07-03T16:39:25","slug":"prognosis-of-covid-19-on-its-1st-anniversary-global-v-s-indian-scenario","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol17no2\/prognosis-of-covid-19-on-its-1st-anniversary-global-v-s-indian-scenario\/","title":{"rendered":"Prognosis of Covid-19 on its 1st Anniversary: Global V\/s Indian Scenario"},"content":{"rendered":"\n

Introduction<\/strong><\/p>\n\n\n\n

The\nCorona virus (Covid-19) is the greatest threat to world health now, and the\ngreatest issue facing the cosmos is pandemic1<\/sup>. Corona viruses, which\ncause sickness in animals and humans, are members of the family Coronaviridae\nof the Nidovirales family. Corona viruses are named after the crown-like spikes\non their outer surface. They are a form of enclosed virus with a non-segmented,\nsingle-stranded, positive-sense RNA genome. Corona virus subgroups include\nalpha, beta, gamma, and delta coronaviruses 2, 3<\/sup>. Seven\ncoronaviruses can infect people all across the world, but the four most\nprevalent are 29E, NL63 (alpha coronavirus), OC43, and HKU1 (beta coronavirus).<\/p>\n\n\n\n

MERS-CoV,\nthe virus responsible for Middle East respiratory disease (MERS), and SARS-CoV,\nthe virus responsible for severe acute respiratory disease (SARS), are rarer\nvariants that induce more severe consequences. A severe new strain of\nSARS-CoV-2 began circulating in 2019, generating the disease COVID-192<\/sup>.\nPrior to the 2002 outbreak of SARS in Guangdong, China, caused by SARS-CoV,\nthese viruses were thought to solely affect animals 3, 4<\/sup>.<\/p>\n\n\n\n

Origin and Transmission<\/strong><\/p>\n\n\n\n

The\nfirst known human coronavirus outbreak, known as HCoV-229E, occurred in 1965.\nTwo subsequent outbreaks of comparable size, known as SARS-CoV and MERS-CoV,\noccurred in 2003 and 2012, respectively 5<\/sup>. CoVs have been found to\nbe human-susceptible viruses, with CoVs HCoV-229E and HCoV-NL63 and CoVs\nHCoV-HKU1 and HCoV-OC43 both causing moderate respiratory symptoms comparable\nto the flu. The other two known CoVs, SARS-CoV and MERS-CoV, cause serious and\npotentially fatal respiratory tract diseases 6<\/sup>. SARS-CoV-2’s genomic\nsequence shared 79.5% similarity with SARS-CoV while sharing 96.2% identity\nwith a bat CoV, RaTG13. According to viral genome sequencing investigations and\nevolutionary studies, the bat is the virus’s natural host, and\nSARSCoV-2 may be transferred from bats to humans via unidentified\nintermediary animals, as seen in figure-13<\/sup>. SARS-CoV-2 may infect\npeople by exploiting the angiotensin-converting enzyme 2 (ACE2) receptor, which\nis the same as SARS-CoV 7<\/sup>. According to WHO reports for 2020, almost\n30% of the nations were unready and had no plans for the spread of COVID-19. In\nhealthcare institutions, a complete infection prevention and control programme,\nas well as water, sanitation, and hygiene requirements, are only found in\nselect countries. In the absence of a COVID-19 vaccine, preserving social and\nphysical distance seeks to limit the spread of this infectious illness 8<\/sup>.<\/p>\n\n\n\n\n\n
\"\"<\/td>\n\n

Figure 1: Transmission of Covid-19 to Human Host.<\/strong><\/p>\n

<\/p>\n

Click here to view Figure<\/a><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n

Epidemiology<\/strong><\/p>\n\n\n\n

The\nfirst case of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)\ninfection, which causes coronavirus illness (COVID-19), was discovered in\nDecember 2019 in Wuhan, China, and quickly spread to many other regions. The\nWorld Health Organisation (WHO) has recorded 69,592,545 positive COVID-19 cases\nas of December 10th<\/sup>, 2020, and the death toll from COVID-19 had\nreached 1,581,854 globally. As of January 24, 2020, at least 830 instances had\nbeen documented in nine countries, including China, Thailand, Japan, South\nKorea, Singapore, Vietnam, Taiwan, Nepal, and the United States. The WHO\nclassified COVID-19 as a public health emergency of international concern on\nJanuary 30, 2020. The most impacted nations on the globe are the United States,\nIndia, Brazil, Russia, and the and the United Kingdom, and a high fatality rate\nis seen in countries like the United States (441K), Brazil (225K), Mexico\n(159K), India (154K), and the United Kingdom (106K). On January 30th, 2020, the\nstate of Kerala reported the first SARS-CoV-2 positive case in India 9, 10<\/sup>.\nFollowing that, just two further instances were recorded in February.  As\nof March 26th, the Indian Council of Medical Research and the Ministry of\nFamily Welfare had confirmed a total of 649 cases, 42 recoveries, 1 migration,\nand 13 fatalities, In India, the COVID-19 infection rate is 1.7, which is far\nlower than in the worst-affected countries 11<\/sup>. The first death in\nIndia was on March 12th<\/sup>, 2020, in Kalaburagi, Karnataka, of a\n76-year-old man with comorbidities of asthma, hypertension, diabetes, and a\nhistory of international travel. More instances occurred in March, and the\nnumber of cases has increased significantly since the second part of April\n2020. According to the Ministry of Health and Family Welfare (MoHFW), as of\nJune 9, 2020, there had been a total of 2,66,598 confirmed COVID-19 cases\nreported by 32 states and union territories 12<\/sup>. The most affected\nstates in India are Maharashtra, Karnataka, Kerala, Andhra Pradesh, Tamil Nadu,\nand Delhi. High fatality rates are seen in states like Maharashtra (51k),\nKarnataka (12.2k), Tamil Nadu (12.3k), Delhi (10.8k), and West Bengal (10.1k).\nOn March 22nd<\/sup>, 2020, the Janta Curfew was declared by the Government\nof India for quarantine and to prevent the spread of disease. Along with its\npositive effects, the government’s harsh public health policy also has negative\neffects on the populace, which can result in social, psychological, and\neconomic stress, which can have long-term detrimental health effects 5<\/sup>.<\/p>\n\n\n\n

Effect on Mental Health<\/strong><\/p>\n\n\n\n

Social\ndeterminants of health include race, gender, ethnicity, sexual orientation,\ndisability status, and resources such as a job, money, food, shelter, and\nsocial supports 13<\/sup>. Health care workers (HCWs) have been observed to\nexperience the psychological effects the most. Long working hours, strict rules\nand regulations, the constant need for attention and attentiveness, limited\nsocial contact, and completing tasks for which one may not have been prepared\nare all instances of extremely high work-related stressors. The COVID-19\npandemic-related emotional discomfort that healthcare workers experienced has\nbeen strongly linked to depression, stress, and anxiety 14<\/sup>. The\npandemic of COVID-19 has had a profound psychological impact, and the social\ninfluence on the population may have an effect on both people’s health, safety,\nand well-being (due to insecurity, confusion, emotional isolation, and stigma)\nas well as communities’ (due to economic loss, closure of workplaces and\neducational institutions, insufficient funding for medical responses, and\nimproper distribution of necessities) safety and well-being. These consequences\ncan manifest as a wide range of emotional reactions (such as distress or\npsychiatric conditions), unhealthy behaviours (such as excessive substance\nabuse), and noncompliance with public health regulations (such as home\nconfinement and vaccination) in both those who contract the disease and the\ngeneral population 15,16,17<\/sup>. COVID-19’s mental health implications\nare being referred to as the “fourth wave” of the pandemic and are\nexpected to be responsible for the greatest and most long-lasting health\nfootprint illustrated in figure 2.<\/p>\n\n\n\n\n\n
\"\"<\/td>\n\n

Figure 2: Four Waves of Covid-19.<\/strong><\/p>\n

<\/p>\n

Click here to view Figure<\/a><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n

Risk factors effecting COVID 19<\/strong><\/p>\n\n\n\n

Risk factors for the Corona virus include older age (geriatric population), pre-existing cardiovascular or cerebrovascular diseases, Diabetes, Obesity, Chronic Kidney Disease (CKD), Chronic Liver Disease, Chronic Lung Illness (Chronic Obstructive Pulmonary Disease (COPD), Asthma, Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF), or Bronchiectasis), Carcinoma, Dyslipidemia, Hypertension, Immune-compromised state (weakened immune system) 18,19<\/sup>. COVID-19 can be spread by direct contact with infected animals or through human-to-human transmission and touching contaminated surfaces, which are the main forms of transmission. Along with risk factors, some clinical findings associated with COVID-19 are shown in Table 1.<\/p>\n\n\n\n

Table 1: Clinical Findings Associated with Covid-19.<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

 <\/u><\/p>\n<\/td>\n

\n

Mild <\/strong><\/p>\n<\/td>\n

\n

Moderate <\/strong><\/p>\n<\/td>\n

\n

 Severe <\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

    SPO2<\/p>\n<\/td>\n

\n

>94% in room air<\/p>\n<\/td>\n

\n

90-94% in room air<\/p>\n<\/td>\n

\n

<90% in room air<\/p>\n<\/td>\n<\/tr>\n

\n

      RR<\/p>\n<\/td>\n

\n

<24\/minute<\/p>\n<\/td>\n

\n

24-30<\/p>\n<\/td>\n

\n

>30<\/p>\n<\/td>\n<\/tr>\n

\n

 <\/p>\n<\/td>\n

\n

No pneumonia<\/p>\n<\/td>\n

\n

Pneumonia +<\/p>\n<\/td>\n

\n

Pneumonia++<\/p>\n<\/td>\n<\/tr>\n

\n

CT Chest Criteria<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

 <\/p>\n<\/td>\n

\n

Normal or <25%<\/p>\n<\/td>\n

\n

25%-75%<\/p>\n<\/td>\n

\n

75%-100%<\/p>\n<\/td>\n<\/tr>\n

\n

 <\/p>\n<\/td>\n

\n

Grade I<\/p>\n<\/td>\n

\n

GradeII\/III<\/p>\n<\/td>\n

\n

Grade IV<\/p>\n<\/td>\n<\/tr>\n

\n

Laboratory Findings<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

NLR<\/p>\n<\/td>\n

\n

<3.2<\/p>\n<\/td>\n

\n

>3.2<\/p>\n<\/td>\n

\n

>5.5<\/p>\n<\/td>\n<\/tr>\n

\n

CRP<\/p>\n<\/td>\n

\n

<40<\/p>\n<\/td>\n

\n

40-125<\/p>\n<\/td>\n

\n

>125<\/p>\n<\/td>\n<\/tr>\n

\n

Ferritin<\/p>\n<\/td>\n

\n

<500<\/p>\n<\/td>\n

\n

>500<\/p>\n<\/td>\n

\n

>800<\/p>\n<\/td>\n<\/tr>\n

\n

D Dimer<\/p>\n<\/td>\n

\n

<0.5<\/p>\n<\/td>\n

\n

>0.5<\/p>\n<\/td>\n

\n

>1.0<\/p>\n<\/td>\n<\/tr>\n

\n

LDH<\/p>\n<\/td>\n

\n

<300<\/p>\n<\/td>\n

\n

300-400<\/p>\n<\/td>\n

\n

>400<\/p>\n<\/td>\n<\/tr>\n

\n

IL6<\/p>\n<\/td>\n

\n

<4.8<\/p>\n<\/td>\n

\n

5-50<\/p>\n<\/td>\n

\n

>80<\/p>\n<\/td>\n<\/tr>\n

\n

LFT<\/p>\n<\/td>\n

\n

Normal<\/p>\n<\/td>\n

\n

Slight derangement<\/p>\n<\/td>\n

\n

Moderate derangement<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n

Treatment<\/strong><\/p>\n\n\n\n

COVID-19\ndoes not have a specific antiviral therapy, and no safer vaccines were\navailable until the end of 2020. The treatment was symptomatic, with oxygen\ntherapy serving as the main treatment intervention for patients with severe\ninfections. Antibiotics were also used to maintain body fluid balance and avoid\nsubsequent bacterial infections. In situations of respiratory failure that is\nresistant to oxygen treatment, mechanical ventilation may be necessary;\nnonetheless, hemodynamic support is crucial for treating septic shock 20<\/sup>.\nPatients with refractory hypoxemia should get extracorporeal membrane\noxygenation (ECMO), according to the WHO. According to their circumstances,\nsome serious patients receive rescue therapy using convalescent plasma and\nimmunoglobulin G 7<\/sup>. The MOHFW and the Government of India have\nimplemented a revised protocol for COVID-19 clinical care. The protocol also\nincludes instructions for investigational medicines, including Remdesivir,\nTocilizumab, Convalescent Plasma Therapy, and a prophylactic dose of low-molecular-weight\nheparin such as Enoxaparin. Corticosteroid dexamethasone has also been included\nin the treatment protocols for COVID-19 patients with moderate to severe\nillness. It is no longer recommended to use azithromycin and hydroxychloroquine\ncombined to treat people with severe Corona virus infections 21<\/sup>.<\/p>\n\n\n\n

Antiviral therapy<\/strong><\/p>\n\n\n\n

Antiviral drugs are Lopinavir\/Ritonavir, Ribavirin, Oseltanavir, Penciclovir\/Acyclovir, Ganciclovir, and Favipiravir. The experimental antiviral drug is Remdesivir. Antiviral medications and systemic corticosteroid therapy, such as neuraminidase inhibitors (Oseltamivir, Peramivir, Zanamivir, etc.), Ganciclovir, Acyclovir, and Ribavirin, as well as methyl prednisolone for influenza virus, are ineffective against COVID-19 and are not indicated 4,7<\/sup>. Remdesivir, a nucleoside analogue and broad-spectrum antiviral, significantly suppresses SARSCoV-2 infection at low micromolar dosages and has a high selectivity index. Ritonavir and Lopinavir (protease inhibitors) can bind to the endopeptidase C30 of the SARS-CoV-2 protease and have an antiviral impact by lowering SARS-CoV-2 protein synthesis. Remdesivir was claimed to have been successful in treating the first COVID case in the United States. Acute Respiratory Distress Syndrome was reduced in severe SARS or MERS patients treated with Lopinavir\/Ritonavir alone or in combination with other antiviral medications, which improved the patients’ prognosis 22<\/sup>.<\/p>\n\n\n\n

Chloroquine<\/strong><\/p>\n\n\n\n

Chloroquine and hydroxychloroquine are widely used anti-malarial, auto-immune disease, and broad spectrum anti-viral drugs. They function by inhibiting the cellular receptor ACE2, impairing endosome acidification, and acting against a range of pro-inflammatory cytokines (including IL-1 and IL-6) 7<\/sup>. One of the first medical authorities in the world to suggest the use of HCQS prophylaxis among healthcare professionals and close associates caring for COVID-19 or suspected patients was the Indian Council of Medical Research. Azithromycin and hydroxychloroquine proved to work better together, according to certain research. Before using hydroxychloroquine, the likelihood of medication toxicity (including QT interval (QTC) prolongation and retinal toxicity) should be considered, especially in people who may be more vulnerable to these effects, such as those with epilepsy, porphyria, myasthenia gravis, and retinal pathology\u2014glucose-6-phosphate dehydrogenase (G6PD) deficiency. Remdesivir and chloroquine together have been shown to successfully suppress the recently emerging SARS-CoV-2 in vitro 20, 22<\/sup>. Hydroxychloroquine was exported from India to other countries like the US, Canada, UK, Mauritius, UAE, Sri Lanka, Russia, the Philippines, Brazil, Germany, Spain, Butan, Nepal, Afghanistan, Syria, etc.<\/p>\n\n\n\n

Glucocorticoids<\/strong><\/p>\n\n\n\n

In individuals with COVID-19 pneumonia, glucocorticoids (Dexamethasone, Methyl Prednisolone) are not advised unless there are other indications (e.g., COPD). Glucocorticoids have been associated with both delayed viral clearance and an increased risk of death in individuals infected with the Middle East respiratory syndrome coronavirus (MERS-CoV) 20<\/sup>. According to Union Health Ministry protocol, dexamethasone is an alternative choice to methyl prednisolone for managing moderate-to-severe COVID-19.<\/p>\n\n\n\n

Immunotherapy<\/strong><\/p>\n\n\n\n

Convalescent plasma treatment has been used for over a decade to provide passive immunity in COVID-19 patients by infusing SARS-CoV-2 convalescent plasma from recovered patients with antiviral antibodies (IgG, IgA, IgM, IgE, and IgD). Convalescent plasma therapy has previously been used to treat a variety of diseases, including influenza, poliomyelitis, influenza A (H5N1), and ebola. The Food and Drug Administration stated in the “Diagnosis and Treatment Guidelines of COVID-19 (trial 6th, 7th, and 8th)” issued by the NHC that delivery and testing of experimental CP therapy may have a therapeutic effect on COVID-19 during the public health emergency 24<\/sup>. Throughout India Convalescent plasma therapy, which can restrict the course of infection and reverse the inflammatory process in COVID-19 patients via numerous pathways, was first used in New Delhi. It also includes immune-modulatory cytokines and autoantibodies, which help to control the hyper-inflammatory process and cytokine storm, eventually improving respiratory function and prognosis in COVID-19 patients. Monoclonal antibodies that target the S1 domain of the SARS CoV, such as 80 R, m396, and S230.15, have been demonstrated to be successful in neutralising SARS-CoV infections by preventing their binding to ACE receptors on host cells 22<\/sup>.<\/p>\n\n\n\n

Cytokine storm<\/strong><\/p>\n\n\n\n

Interleukin (IL)-1, IL-6, IL-12, interferon (IFN), and tumour necrosis factor (TNF) are cytokines that primarily target lung tissue25<\/sup>. A well-known clinical syndrome called cytokine storm is defined by a massive production of pro-inflammatory cytokines that triggers an out-of-control immune response that damages organs. Particularly in tissues like the colon and kidney that express high levels of ACE2, the cytokine storm will cause harm. The use of mesenchymal stem cells that have been cytokine activated during treatment can cease the inflammatory process and aid in tissue repair 26<\/sup>. According to a report from China, COVID-19 targeting cytokine storms is frequent in older people. Immune modulation may be required for COVID-19 at its most severe stages, in addition to antiviral and supportive therapies 27<\/sup>.<\/p>\n\n\n\n

Interferons<\/strong><\/p>\n\n\n\n

Interferons are critical cytokines used in the therapy of cancer, autoimmune disorders, and hepatitis B and C. IFN is a type I IFN that inhibits viral infection by interfering with virus replication and activating immune responses, both innate and adaptive. In vitro tests revealed that IFN efficiently inhibits SARS-CoV multiplication. Clinical and observational studies of SARS-CoV patients revealed a lack of cytokines, IFN-\u03b1 and IFN-\u03b2, as compared to influenza patients 28<\/sup>. COVID-19 patients have been found to have lower levels of IFN-\u03b1 and IFN-\u03b2. IFNs were believed to be systemically efficient in restoring lung function or delaying mortality in SARS and MERS-CoV, but they generally failed to appreciably ameliorate the disease in humans 29<\/sup>.  Potential drugs and their target sites, along with the replication mechanism of SARS-CoV2, are shown in Figure 3.<\/p>\n\n\n\n\n\n
\"\"<\/td>\n\n

Figure 3: Replication Mechanism and Potential Drug Targets of SARS-COV2.<\/strong><\/p>\n

<\/p>\n

Click here to view Figure<\/a><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n

Need for Vaccine<\/strong><\/p>\n\n\n\n

When combined with good testing and existing prevention efforts, a COVID-19 vaccine will be a vital instrument in bringing the pandemic under control. Although Remdesivir, an antiviral medicine, is available in developed countries, it has been demonstrated to be beneficial in treating COVID-19 illness symptoms and hastening recovery3<\/sup>. Several companies have agreed to develop a COVID-19 vaccine that particularly targets SARS-CoV2. A range of strategies, including live-attenuated virus, viral proteins, viral nucleic acid, virus-like particles, peptides, viral vectors (replicating and non-replicating), and recombinant protein approaches, are being employed to develop a vaccine against SARS-CoV-2 23, 27<\/sup>. Some of the approved vaccines by different governments worldwide are listed in Table 2.<\/p>\n\n\n\n

Table 2: Approved Vaccines All Over the World. <\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Manufacturer & Vaccine <\/strong><\/p>\n<\/td>\n

\n

Country <\/strong><\/p>\n<\/td>\n

\n

Efficacy <\/strong><\/p>\n<\/td>\n

\n

Type of vaccine <\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Oxford university Astra Zeneca<\/p>\n<\/td>\n

\n

U.K, India<\/p>\n<\/td>\n

\n

Up to 90%<\/p>\n<\/td>\n

\n

Viral vector (Genetically modified virus)<\/p>\n<\/td>\n<\/tr>\n

\n

Bharat biotech<\/p>\n

ICMR- Covaxin<\/p>\n<\/td>\n

\n

India<\/p>\n<\/td>\n

\n

80.6%<\/p>\n<\/td>\n

\n

Inactivated<\/p>\n<\/td>\n<\/tr>\n

\n

Serum Institute of India- Covishield<\/p>\n<\/td>\n

\n

India<\/p>\n<\/td>\n

\n

70.4%<\/p>\n<\/td>\n

\n

Non replicating viral vector<\/p>\n<\/td>\n<\/tr>\n

\n

BioNtech- Pfizer<\/p>\n<\/td>\n

\n

Germany, America<\/p>\n<\/td>\n

\n

95%<\/p>\n<\/td>\n

\n

RNA<\/p>\n<\/td>\n<\/tr>\n

\n

Moderna- National Institute of allergy and infectious diseases<\/p>\n<\/td>\n

\n

Canada<\/p>\n

U.S.A<\/p>\n<\/td>\n

\n

94.50%<\/p>\n<\/td>\n

\n

RNA<\/p>\n<\/td>\n<\/tr>\n

\n

Gamaleya research centre<\/p>\n<\/td>\n

\n

Russia<\/p>\n<\/td>\n

\n

91.4%<\/p>\n<\/td>\n

\n

Viral vector<\/p>\n<\/td>\n<\/tr>\n

\n

CanSino biologics<\/p>\n<\/td>\n

\n

China<\/p>\n<\/td>\n

\n

65.7%<\/p>\n<\/td>\n

\n

Viral vector<\/p>\n<\/td>\n<\/tr>\n

\n

Vector institute<\/p>\n<\/td>\n

\n

Russia<\/p>\n<\/td>\n

\n

100%<\/p>\n<\/td>\n

\n

Peptide antigens<\/p>\n<\/td>\n<\/tr>\n

\n

Sinovac biotech<\/p>\n<\/td>\n

\n

China<\/p>\n<\/td>\n

\n

>50%<\/p>\n<\/td>\n

\n

Inactivated Virus<\/p>\n<\/td>\n<\/tr>\n

\n

Sinopharm<\/p>\n<\/td>\n

\n

China, U.A.E, Bahrain<\/p>\n<\/td>\n

\n

79%<\/p>\n<\/td>\n

\n

Inactivated Virus<\/p>\n<\/td>\n<\/tr>\n

\n

Novavax<\/p>\n<\/td>\n

\n

Russia<\/p>\n<\/td>\n

\n

96.4%<\/p>\n<\/td>\n

\n

Protein based<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n

Pfizer & Moderna are COVID-19 mRNA\nvaccines approved by the Medicines and Health Products Regulatory Agency in the\nU.K. This is the first emergency use authorization granted following a global\nphase 3 study of a pandemic vaccine 31<\/sup>. The US Food and Drug\nAdministration issued the first emergency use license of vaccines for the\nprevention of COVID-19 for anyone over the age of 16 on December 11, 2020.\nSoreness at the injection site, weariness, headache, muscular soreness, chills,\njoint pain, and fever were described as common mild to moderate adverse effects\nthat often lasted several days during the second dose rather than the first\ntreatment. For the existing side effects, the developers are constantly\nanalysing the vaccine’s safety and tolerance 32<\/sup>.<\/p>\n\n\n\n

The first vaccine developed in India, “Covaxin” by Bharat Biotech ICMR, is an inactivated whole virus vaccine for BBV 152 that has successfully completed Phase 1 (375 subjects) and Phase 2 (380 subjects) trials. The virus strain used in these trials was obtained from the Indian ICMR National Institute of Virology, Pune. The DNA-based second vaccination in India, “ZyCovD,” produced by Zydus Cadila, has completed Phase 1 and Phase 2 trials (1048 individuals), and following Phase 3, it may receive fast track approval from DCGI 33<\/sup>. A restricted emergency approval for Covaxin and Covishield (the Oxford-AstraZeneca-designed vaccine that is also produced in India) was given by the country’s medicines authorities in January 2021. On January 16, 2021, India initiated the world’s largest COVID-19 vaccination campaign, with a target population of 300 million people 34<\/sup>.<\/p>\n\n\n\n

Conclusion<\/strong><\/p>\n\n\n\n

As the disease is growing at an alarming\nrate around the world, the COVID-19 pandemic has raised problems for almost\nevery industry1<\/sup>. Even though the state-wide lockdown has slowed the\nspread of COVID-19, the country’s constantly rising population, extraordinarily\nhigh population density, and deplorable socioeconomic conditions are important\ndifficulties in India’s struggle 12<\/sup>. Transmission of the virus can\nbe prevented by adhering to the safety guidelines issued by the WHO and their\nrespective governments. Specific therapy was not available, but it can be\nmanaged to some extent by the available drugs, and no safer vaccine was available\nuntil the end of 2020. Several companies taking initiative for the development\nof vaccines and vaccination programmes were taking place in India for the\nprevention of the COVID-19 pandemic. <\/p>\n\n\n\n

References<\/strong><\/p>\n\n\n\n

  1. Albaraa M. Current situation of Corona virus Disease: (COVID-19) review article. Health Science Journal. 2020;1(1):1-4.<\/li>
  2. Shrikrushna S, Shubham S, Suraj T. A Review on Corona Virus (COVID-19). World Journal of Pharmaceutical and Life Sciences. 2020;6(4):109-115.<\/li>
  3. Muhammad A, Suliman K, Abeer K. COVID-19 infection: Origin, transmission and characteristic of human corona viruses. Journal of Advanced Research. 2020;24(1):91-98.
    CrossRef <\/a><\/li>
  4. Abdul H, Shmmon A, Sameera S. A Review of COVID-19 (Corona virus Disease-2019) Diagnosis, Treatments and Prevention. Eurasian Journal of Medicine and Oncology. 2020;4(2):116-125.<\/li>
  5. Pranab C, Nazia N, Anup A. The 2019 novel corona virus disease (COVID-19) pandemic: A review of the current scenario. Indian Journal of Medical Research. 2020;151(1):147-159.
     CrossRef <\/a><\/li>
  6. Aritra G, Srijita N, Tapas M. How India is dealing with COVID-19 pandemic. Sensors International. 2020;1(1):1-9.
     CrossRef <\/a><\/li>
  7. Yan-rong G, Qing-dong C, Zhong-si H. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medical Research. 2020;7(11):1-10.
     CrossRef <\/a><\/li>
  8. Nilima N, Siddharth K, Bhaskar T. Psycho-social factors associated with the national wide lockdown in India during COVID-19 pandemic. Clinical Epidemiology and Global Health. 2021;9(1):47-52.
    CrossRef <\/a><\/li>
  9. Udhayakumar S, Thirumalkumar D, Prabhu C. The Rise and Impact of COVID-19 in India. Frontiers in Medicine. 2020;7(1):1-7.
     CrossRef <\/a><\/li>
  10. David M, Lokeshwar P, Suraj D. COVID-19 (CORONAVIRUS): A Global Emergency Outbreak and Implications in India. International Journal of Zoology and Applied Biosciences. 2020;5(2):89-98.<\/li>
  11. Varsha K. Novel Corona virus (COVID-19) in India: Current scenario. International Journal of Research and Review. 2020;7(3):435-447.<\/li>
  12. Rimesh P, Urmila Y. Covid-19 pandemic in India: Present scenario and steep climb ahead. Journal of Primary Care & Community Health. 2020;11(1):1-4.
     CrossRef <\/a><\/li>
  13. Emily J, Corey M, Saima H. A portrait of the early and differential mental health impacts of the COVID-19 pandemic in Canada: Findings from the first wave of a nationally representative cross sectional survey. Preventive Medicine. 2020;1(1):1-12.<\/li>
  14. Javier S, Juan B, Darren M. Prevalence of anxiety in health care professionals during COVID-19 pandemic: A rapid systemic review (on published articles in Medline) with meta analysis. Progress in Neuropsychopharmacology and Biological Psychiatry. 2021;107(1):1-15.
     CrossRef <\/a><\/li>
  15. Valeria S, Davide A, Vincenzo A. The Psychology and Social Impact of Covid-19: New Perspectives of Well-Being. Frontiers in Psychology. 2020;11(1):1-6.
     CrossRef <\/a><\/li>
  16. Jianbo L, Simeng M, Ying W. Factors associated with mental health outcomes among health care workers exposed to corona virus disease. JAMA. 2020;3(3):1-12.
    CrossRef <\/a><\/li>
  17. Betty P, Carol S. Mental Health and the COVID-19 Pandemic. The New England Journal of Medicine. 2020;6(383):510-512.
     CrossRef<\/a> <\/li>
  18. Tao L, Wenjia L, Haojie Z. Risk factors associated with COVID-19 infection: a retrospective cohort study based on contacts tracing. Emerging Microbes & Infections. 2020;9(1):1-10.
     CrossRef <\/a><\/li>
  19. Min cheol C, Yu-kyung P, Bong-ok K. Risk factors for disease progression in COVID-19 patients. BMC Infectious Disease. 2020;20(445):1-6.
     CrossRef <\/a><\/li>
  20. Francesco D, Damiano P, Claudia M. CoronaVirus Diseases (COVID-19) Current Status and Future Perspective: A Narrative Review. International Journal of Environmental Research and Public Health. 2020;17(1):1-11.
     CrossRef <\/a><\/li>
  21. Sugin S, Ananthalakshmi V. The current situation of COVID-19 in India. Brain, Behavior and Immunity- Health. 2021;11(1):1-5.
     CrossRef <\/a><\/li>
  22. Heng L, Shang-ming L, Xiao-hua Y. Corona virus Disease (COVID-19): Current Status and Future Perspectives. International Journal of Antimicrobial Agents.2020;55(1):1-9.<\/li>
  23. Harmanjit S, Prerna C, Ashishkumar K. Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. European Journal of Pharmacology. 2021;1(1):1-11.<\/li>
  24. Ying W, Pengfei H, Rulin D. Convalescent plasma therapy may be a possible treatment for COVID-19: A systemic review. International Immunopharmacology. 2021;91(1):1-18.
     CrossRef <\/a><\/li>
  25. Rishabh H, Mohdaslam S, Chandraiah G. Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications. Life Sciences. 2020;267(1):1-14.
     CrossRef <\/a><\/li>
  26. Faheem P, Tareq A, Abdallah M. Immune system response during viral infections: Immunomodulators, Cytokine storm and Immunotherapeutics in COVID-19. Saudi Pharmaceutical Journal. 2020;1(1):1-15.
    CrossRef <\/li>
  27. Yatin M, Subhal D, Kapil Z. Cytokine storm in novel Corona Virus Disease (COVID-19): Expert management consideration. Indian Journal of Critical Care Medicine. 2020;24(6):429-434.
    CrossRef <\/a><\/li>
  28. Bianza M, Feng H, Tiatou S.Prevention and treatment of COVID-19: Focus on interferons, chloroquine\/hydroxychloroquine, azithromycin and vaccine. Biomedicine and Pharmacotherapy. 2021;133(1):1-20.
     CrossRef <\/a><\/li>
  29. Parastoo T, Samane E, Milad C. A review of potential suggested drugs for Corona virus Disease (COVID-19) treatment. European Journal of Pharmacology. 2021;21(1):1-87. <\/li>
  30. Pfizer and Biotech achieve first authorization in the world for a vaccine to combat Covid-19. December 02, 2020. https:\/\/www. pfizer.com\/ news\/press-release\/press-release-detail\/p<\/li>
  31. A side by side comparison of the Pfizer biotech and Moderna vaccines. December 12, 2020. Available from: https:\/\/www.statnews.com\/ 2020\/12\/19\/a-side-by-side-comparison-of-the-pfizer-biontech-and-moderna-vaccines\/<\/li>
  32. Shashank J. COVID-19 Immunity to Vaccination in India. JAPI. 2021;69(4):1-3.<\/li>
  33. Bhuyan A. World report. India begins COVID-19 vaccination amid trial allegations. 2021;397:1.
     CrossRef <\/a><\/li>
  34. Bagcchi S. The world’s largest COVID-19 vaccination campaign. Lancet Infect Dis. 2021 Mar;21(3):323.
     CrossRef <\/a><\/li><\/ol>\n","protected":false},"excerpt":{"rendered":"

    Introduction The Corona virus (Covid-19) is the greatest threat to […]<\/p>\n","protected":false},"author":15,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[115],"tags":[],"class_list":["post-58592","post","type-post","status-publish","format-standard","hentry","category-vol17no2"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/58592","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=58592"}],"version-history":[{"count":5,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/58592\/revisions"}],"predecessor-version":[{"id":59543,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/58592\/revisions\/59543"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=58592"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=58592"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=58592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}